UNSPSC 51123201: Aprindine

This classification denotes an antiarrhythmic agent with the molecular formula C22H30N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 5Y48085P9Q, chemically known as 1,3-propanediamine, n-(2, 3-dihydro-1h-inden-2-yl)-n,n-diethyl-n-phenyl-, monohydrochloride but more generally known as aprindine, which bears US NIH Compound Identifier 2218. Aprindine most often comes in base and hydrochloride forms.

UNSPSC 51123201 Aprindine (Commodity) reflects state and local procurement of advanced life support and emergency pharmaceuticals, with recent solicitations spanning direct supply contracts for emergency medical services and multi-state cooperative purchasing agreements for generic and over-the-counter medications. The code captures what state and local governments actually buy under its nominal scope: individual medication line items — including emergency-response drugs such as epinephrine, labetalol, adenosine, and diltiazem — supplied to fire rescue services, public health agencies, and state employee benefit programs. Issuing bodies include municipal purchasing departments (City of Tampa), state health agencies (Texas Health and Human Services Commission), and multi-state cooperative purchasing consortia (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The mix skews toward state health and human services agencies managing pharmacy benefits at scale and municipal emergency services procurement offices, with MMCAP serving as a significant aggregator vehicle for state and local participation across multiple jurisdictions.

Recent activity centers on Florida, Texas, and Minnesota through the MMCAP cooperative, which extends to participating states including Oregon. The City of Tampa Purchasing Department issued an IFB (Bid No. 26-P-00188) on April 24, 2026, with a due date of April 8, 2026, for Advanced Life Support Medications to supply Tampa Fire Rescue with 370 units of Labetalol HCl 100mg vials, 1,810 units of Epinephrine 1:10,000 injections, 330 units of Adenosine 6mg vials, and 1,020 units of Diltiazem 25mg vials, with an estimated contract value of $40,000 and a Small Local Business Enterprise (SLBE) 5 percent bid discount available. The Texas HHS Commission issued an RFI (HHS0017013) on April 3, 2026, to gather market intelligence on direct-to-manufacturer prescription fulfillment strategies without established budget or timeline. MMCAP's RFP (S1070000015802), due March 26, 2026, sought multiple manufacturers for generic pharmaceuticals and OTC products distributed through three authorized wholesalers, with award effective July 1, 2026, and performance penalties ranging from $200 to $1,500 per violation for reporting and onboarding failures.